These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 16216042)
1. Synthesis and biological evaluation of novel EG5 inhibitors. Sarli V; Huemmer S; Sunder-Plassmann N; Mayer TU; Giannis A Chembiochem; 2005 Nov; 6(11):2005-13. PubMed ID: 16216042 [TBL] [Abstract][Full Text] [Related]
2. New chemical tools for investigating human mitotic kinesin Eg5. Klein E; DeBonis S; Thiede B; Skoufias DA; Kozielski F; Lebeau L Bioorg Med Chem; 2007 Oct; 15(19):6474-88. PubMed ID: 17587586 [TBL] [Abstract][Full Text] [Related]
3. Molecular dissection of the inhibitor binding pocket of mitotic kinesin Eg5 reveals mutants that confer resistance to antimitotic agents. Brier S; Lemaire D; DeBonis S; Forest E; Kozielski F J Mol Biol; 2006 Jul; 360(2):360-76. PubMed ID: 16780877 [TBL] [Abstract][Full Text] [Related]
4. Significant decrease of ADP release rate underlies the potent activity of dimethylenastron to inhibit mitotic kinesin Eg5 and cancer cell proliferation. Sun L; Sun X; Xie S; Yu H; Zhong D Biochem Biophys Res Commun; 2014 May; 447(3):465-70. PubMed ID: 24732354 [TBL] [Abstract][Full Text] [Related]
5. Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol. Kaan HY; Ulaganathan V; Rath O; Prokopcová H; Dallinger D; Kappe CO; Kozielski F J Med Chem; 2010 Aug; 53(15):5676-83. PubMed ID: 20597485 [TBL] [Abstract][Full Text] [Related]
6. Identification of MAC1: A Small Molecule That Rescues Spindle Bipolarity in Monastrol-Treated Cells. Al-Obaidi N; Mitchison TJ; Crews CM; Mayer TU ACS Chem Biol; 2016 Jun; 11(6):1544-51. PubMed ID: 27121275 [TBL] [Abstract][Full Text] [Related]
7. Identification of the protein binding region of S-trityl-L-cysteine, a new potent inhibitor of the mitotic kinesin Eg5. Brier S; Lemaire D; Debonis S; Forest E; Kozielski F Biochemistry; 2004 Oct; 43(41):13072-82. PubMed ID: 15476401 [TBL] [Abstract][Full Text] [Related]
9. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5. DeBonis S; Simorre JP; Crevel I; Lebeau L; Skoufias DA; Blangy A; Ebel C; Gans P; Cross R; Hackney DD; Wade RH; Kozielski F Biochemistry; 2003 Jan; 42(2):338-49. PubMed ID: 12525161 [TBL] [Abstract][Full Text] [Related]
10. Development and biological evaluation of potent and specific inhibitors of mitotic Kinesin Eg5. Gartner M; Sunder-Plassmann N; Seiler J; Utz M; Vernos I; Surrey T; Giannis A Chembiochem; 2005 Jul; 6(7):1173-7. PubMed ID: 15912555 [No Abstract] [Full Text] [Related]
11. Validating the mitotic kinesin Eg5 as a therapeutic target in pancreatic cancer cells and tumor xenografts using a specific inhibitor. Liu M; Yu H; Huo L; Liu J; Li M; Zhou J Biochem Pharmacol; 2008 Jul; 76(2):169-78. PubMed ID: 18539263 [TBL] [Abstract][Full Text] [Related]
12. Preferential killing of tetraploid tumor cells by targeting the mitotic kinesin Eg5. Rello-Varona S; Vitale I; Kepp O; Senovilla L; Jemaá M; Métivier D; Castedo M; Kroemer G Cell Cycle; 2009 Apr; 8(7):1030-5. PubMed ID: 19270519 [TBL] [Abstract][Full Text] [Related]
13. Structure of human Eg5 in complex with a new monastrol-based inhibitor bound in the R configuration. Garcia-Saez I; DeBonis S; Lopez R; Trucco F; Rousseau B; Thuéry P; Kozielski F J Biol Chem; 2007 Mar; 282(13):9740-9747. PubMed ID: 17251189 [TBL] [Abstract][Full Text] [Related]
14. KSP inhibitors as antimitotic agents. Pérez-Melero C Curr Top Med Chem; 2014; 14(20):2286-311. PubMed ID: 25434354 [TBL] [Abstract][Full Text] [Related]
15. Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5. Maliga Z; Kapoor TM; Mitchison TJ Chem Biol; 2002 Sep; 9(9):989-96. PubMed ID: 12323373 [TBL] [Abstract][Full Text] [Related]
16. Eg5 targeting agents: From new anti-mitotic based inhibitor discovery to cancer therapy and resistance. Garcia-Saez I; Skoufias DA Biochem Pharmacol; 2021 Feb; 184():114364. PubMed ID: 33310050 [TBL] [Abstract][Full Text] [Related]
17. The effect of adjuvant dimethylenastron, a mitotic Kinesin Eg5 inhibitor, in experimental glaucoma filtration surgery. Lüke J; Nassar K; Lüke M; Tura A; Merz H; Giannis A; Grisanti S Curr Eye Res; 2010 Dec; 35(12):1090-8. PubMed ID: 20961218 [TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of new tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin Eg5. Sunder-Plassmann N; Sarli V; Gartner M; Utz M; Seiler J; Huemmer S; Mayer TU; Surrey T; Giannis A Bioorg Med Chem; 2005 Nov; 13(22):6094-111. PubMed ID: 16084101 [TBL] [Abstract][Full Text] [Related]
19. Impaired angiogenesis and tumor development by inhibition of the mitotic kinesin Eg5. Exertier P; Javerzat S; Wang B; Franco M; Herbert J; Platonova N; Winandy M; Pujol N; Nivelles O; Ormenese S; Godard V; Becker J; Bicknell R; Pineau R; Wilting J; Bikfalvi A; Hagedorn M Oncotarget; 2013 Dec; 4(12):2302-16. PubMed ID: 24327603 [TBL] [Abstract][Full Text] [Related]
20. In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities. DeBonis S; Skoufias DA; Lebeau L; Lopez R; Robin G; Margolis RL; Wade RH; Kozielski F Mol Cancer Ther; 2004 Sep; 3(9):1079-90. PubMed ID: 15367702 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]